Addressing the Challenges of Psoriasis Management: Optimal Treatment Strategies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AbbVie, Celgene, and UCB, Inc.

Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million Americans, or just over 2%, of the US population. Psoriasis is a periodic flare-up of sharply defined red patches, covered by a silvery, flaky surface. This under diagnosed condition most commonly appears on the skin of the scalp, elbow, knees, and lumbosacral areas of the body. Psoriasis is complex to manage, but the goal should be a patient-centered treatment that reduces disease burden, improves quality-of-life, and addresses the risks of systemic complications and comorbid conditions. Co-morbidities associated with the disease include psoriatic arthritis, cardiovascular disease, type 2 diabetes, depression, obesity and more. Psoriasis is estimated to cost $135 billion a year (to include direct and indirect figures) however early diagnosis and treatment can reduce the economic burden. Several traditional treatment options are available ranging from prescribed or over the counter topical treatments, phototherapy, and oral or injected systemic agents. Thankfully novel targeted small molecule medications and biologics have recently become available. Biologics are administered through injection or intravenously and target specific areas of the immune system. These therapies have proven to be efficacious and have demonstrated a significant safety advance over traditional systemic therapies.

Upon completion of this activity, participants will be able to:

  • Analyze the current and emerging agents approved for psoriasis, their mechanisms, and efficacy and safety data, with a close look at emerging therapies that inhibit IL-17 and IL-23

  • Asses the role of PDE4 inhibitors in the management of psoriasis

  • Discuss the appropriate tools for psoriasis diagnosis, including advanced digital imaging

  • Examine the current evidence and data on targeted therapies used to treat plaque psoriasis

  • Address the challenges of managing psoriasis, including adverse effects, comorbid conditions, and medication adherence

  • Explore the role of an interprofessional care team to improve outcomes for patients with psoriasis
     

Faculty: Gary Owens, MD
President
Gary Owens Associates

Disclosure:

Dr. Owens serves as a consultant for Celgene, Janssen, and Novartis. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AbbVie, Celgene, and UCB, Inc.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue